Dr. Nadiesda Costa will discuss the utilization of Prospera, a minimally invasive, cfDNA test to monitor post-transplant patients. She will explain how she uses this tool to successfully manage the status of patients. Dr. Costa will also present case studies that demonstrate the positive, clinical utility of Prospera as well. Ms. Beth Jiorle, MS, CGC will also be presenting Renasight, Natera's premier, 382 kidney gene panel for CKD patients and their families. Beth will provide information about the clinical utility…